Cargando…
Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients
The aim of this study was to evaluate the role of WT1 expression after allogeneic stem cell transplantation (alloHSCT) in patients with acute myeloid leukemia (AML). We studied WT1 expression in bone marrow cells from 50 patients in complete remission on day +60 after transplant. WT1 was assessed on...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471009/ https://www.ncbi.nlm.nih.gov/pubmed/36119469 http://dx.doi.org/10.3389/fonc.2022.994366 |
_version_ | 1784788969586688000 |
---|---|
author | Chiusolo, Patrizia Metafuni, Elisabetta Minnella, Gessica Giammarco, Sabrina Bellesi, Silvia Rossi, Monica Sorà, Federica Limongiello, Maria Assunta Frioni, Filippo Piccirillo, Nicola Bianchi, Maria Valentini, Caterina Giovanna Teofili, Luciana Sica, Simona Bacigalupo, Andrea |
author_facet | Chiusolo, Patrizia Metafuni, Elisabetta Minnella, Gessica Giammarco, Sabrina Bellesi, Silvia Rossi, Monica Sorà, Federica Limongiello, Maria Assunta Frioni, Filippo Piccirillo, Nicola Bianchi, Maria Valentini, Caterina Giovanna Teofili, Luciana Sica, Simona Bacigalupo, Andrea |
author_sort | Chiusolo, Patrizia |
collection | PubMed |
description | The aim of this study was to evaluate the role of WT1 expression after allogeneic stem cell transplantation (alloHSCT) in patients with acute myeloid leukemia (AML). We studied WT1 expression in bone marrow cells from 50 patients in complete remission on day +60 after transplant. WT1 was assessed on unfractionated bone marrow mononuclear cells (MNC) and on CD34+ selected cells (CD34+). A ROC curve analysis identified 800 WT1 copies on CD34+ selected cells, as the best cut-off predicting relapse (AUC 0.842, p=0.0006, 85.7% sensitivity and 81.6% specificity) and 100 copies in MNC (AUC 0.819, p=0.007, 83.3% sensitivity and 88.2% specificity). Using the 800 WT1 copy cut off in CD34+ cells, the 2 year cumulative incidence of relapse was 12% vs 38% (p=0.005), and 2 year survival 88% vs 55% (p=0.02). Using the 100 WT1 copy cut off in unfractionated MNC, the 2 year cumulative incidence of relapse 13% vs 44% (p=0.01) and the 2 year survival 88% vs 55% (p=0.08). In a multivariate Cox analysis WT1 expression in CD34 cells proved to highly predictive of relapse (p=0.004); also WT1 expression on unfractionated cells predicted relapse (p=0.03). In conclusion, day-60 WT1 expression after allogeneic HSCT is a significant predictor of relapse, particularly when tested on CD34+ selected bone marrow cells. |
format | Online Article Text |
id | pubmed-9471009 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94710092022-09-15 Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients Chiusolo, Patrizia Metafuni, Elisabetta Minnella, Gessica Giammarco, Sabrina Bellesi, Silvia Rossi, Monica Sorà, Federica Limongiello, Maria Assunta Frioni, Filippo Piccirillo, Nicola Bianchi, Maria Valentini, Caterina Giovanna Teofili, Luciana Sica, Simona Bacigalupo, Andrea Front Oncol Oncology The aim of this study was to evaluate the role of WT1 expression after allogeneic stem cell transplantation (alloHSCT) in patients with acute myeloid leukemia (AML). We studied WT1 expression in bone marrow cells from 50 patients in complete remission on day +60 after transplant. WT1 was assessed on unfractionated bone marrow mononuclear cells (MNC) and on CD34+ selected cells (CD34+). A ROC curve analysis identified 800 WT1 copies on CD34+ selected cells, as the best cut-off predicting relapse (AUC 0.842, p=0.0006, 85.7% sensitivity and 81.6% specificity) and 100 copies in MNC (AUC 0.819, p=0.007, 83.3% sensitivity and 88.2% specificity). Using the 800 WT1 copy cut off in CD34+ cells, the 2 year cumulative incidence of relapse was 12% vs 38% (p=0.005), and 2 year survival 88% vs 55% (p=0.02). Using the 100 WT1 copy cut off in unfractionated MNC, the 2 year cumulative incidence of relapse 13% vs 44% (p=0.01) and the 2 year survival 88% vs 55% (p=0.08). In a multivariate Cox analysis WT1 expression in CD34 cells proved to highly predictive of relapse (p=0.004); also WT1 expression on unfractionated cells predicted relapse (p=0.03). In conclusion, day-60 WT1 expression after allogeneic HSCT is a significant predictor of relapse, particularly when tested on CD34+ selected bone marrow cells. Frontiers Media S.A. 2022-08-31 /pmc/articles/PMC9471009/ /pubmed/36119469 http://dx.doi.org/10.3389/fonc.2022.994366 Text en Copyright © 2022 Chiusolo, Metafuni, Minnella, Giammarco, Bellesi, Rossi, Sorà, Limongiello, Frioni, Piccirillo, Bianchi, Valentini, Teofili, Sica and Bacigalupo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Chiusolo, Patrizia Metafuni, Elisabetta Minnella, Gessica Giammarco, Sabrina Bellesi, Silvia Rossi, Monica Sorà, Federica Limongiello, Maria Assunta Frioni, Filippo Piccirillo, Nicola Bianchi, Maria Valentini, Caterina Giovanna Teofili, Luciana Sica, Simona Bacigalupo, Andrea Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients |
title | Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients |
title_full | Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients |
title_fullStr | Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients |
title_full_unstemmed | Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients |
title_short | Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients |
title_sort | day +60 wt1 assessment on cd34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471009/ https://www.ncbi.nlm.nih.gov/pubmed/36119469 http://dx.doi.org/10.3389/fonc.2022.994366 |
work_keys_str_mv | AT chiusolopatrizia day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients AT metafunielisabetta day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients AT minnellagessica day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients AT giammarcosabrina day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients AT bellesisilvia day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients AT rossimonica day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients AT sorafederica day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients AT limongiellomariaassunta day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients AT frionifilippo day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients AT piccirillonicola day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients AT bianchimaria day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients AT valentinicaterinagiovanna day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients AT teofililuciana day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients AT sicasimona day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients AT bacigalupoandrea day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients |